A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients with Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Clinical Study with Patisiran

Trial Profile

A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients with Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Clinical Study with Patisiran

Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Patisiran (Primary)
  • Indications Amyloid polyneuropathy
  • Focus Adverse reactions
  • Acronyms APOLLO-OLE
  • Sponsors Alnylam Pharmaceuticals
  • Most Recent Events

    • 03 Nov 2017 According to an Alnylam Pharmaceuticals media release, results are published at the 1st European ATTR Amyloidosis Meeting, for patients (n=24) those were enrolled from phase II OLE study in this global OLE study. Patients completed the treatment for 36 months.
    • 02 Nov 2017 Results published in an Alnylam Pharmaceuticals Media Release.
    • 04 Sep 2017 Planned End Date changed from 1 Jan 2018 to 1 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top